## FINANCIAL AUTHORISATIONS AND DELEGATIONS

## Financial authorisations and delegations in effect as of the date of the Combined General Meeting of 17 April 2025

The following table summarises financial authorisations and delegations granted by the General Meeting to the Board of Directors and still in effect, and the use made of such authorisations in the 2024 financial year. None of these authorisations or delegations was used in the 2024 financial year.

Authorisations and delegations	Maximum nominal amount of capital increases	Maximum nominal amount of debt securities	Validity of authorisation		Combined General Meeting giving the I authorisation	Resolution number	Use made of authorisation during the financial year
SHARE BUYBACKS AND CAPITAL REDUCT	IONS						
Purchase by the Company of its own shares	10% of capital		18 months	17/10/2025	17/04/2024	15	Authorisation not used
Capital reduction through cancellation of shares	10% of share capital per 24 month period		18 months	17/10/2025	17/04/2024	16	Authorisation not used
ISSUANCE OF SECURITIES							
Capital increase with PR <sup>(1)</sup>	€8.4m	€600m	26 months	14/06/2025	14/04/2023	16	Authorisation not used
Capital increase by incorporation on share premium, reserves or profits	€400m		26 months	14/06/2025	14/04/2023	17	Authorisation not used
Capital increase without PR <sup>(1)</sup> by public offering	€4.2m	€600m	26 months	14/06/2025	14/04/2023	18	Authorisation not used
Capital increase without PR <sup>(1)</sup> by private placement	10% of share capital per 12-month period/€4.2m	€600m	26 months	14/06/2025	14/04/2023	19	Authorisation not used
Setting of issue price without PR <sup>(2)</sup> of equity or other securities	10% of capital		26 months	14/06/2025	14/04/2023	20	Authorisation not used
Increase in number of securities to be issued in the event of a capital increase with or without PR <sup>(1)</sup>	15% of initial issue		26 months	14/06/2025	14/04/2023	21	Authorisation not used
Capital increase without PR <sup>(2)</sup> to remunerate in-kind contributions granted to TF1 and consisting of shares or securities giving access to the capital of another company outside of a public exchange offer	10% of capital	€600m	26 months	14/06/2025	14/04/2023	22	Authorisation not used
Capital increase without PR <sup>(2)</sup> to remunerate securities tendered as part or a public exchange offer initiated by TF1	€4.2m	€600m	26 months	14/06/2025	14/04/2023	23	Authorisation not used
ISSUES RESERVED FOR EMPLOYEES AN	D EXECUTIVE OFFI	CERS					
Capital increase without PR <sup>(1)</sup> reserved for employees and/or Corporate Officers of TF1 or related companies participating in a company savings scheme (PEE)	2% of capital		26 months	14/06/2024	14/04/2023	24	Authorisation not used
Granting of stock options and/or share purchases to the employees and Corporate Officers of TF1 or related companies	3% of capital		38 months	14/06/2025	14/04/2022	19	725,000 stock options were granted (0.34% of capital)
Granting of existing free shares or free shares to be issued to the employees or Corporate Officers of TF1 or related companies without PR <sup>(1)(2)</sup>	3% of capital		38 months	14/06/2025	14/04/2022	20	995,000 stock options were granted (0.47% of capital)

(1) PR: preferential right of subscription.
(2) Awarded subject to performance conditions. Common ceiling. No grants were awarded to the Chairman and Chief Executive Officer.

€m: millions of euros.